3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Endocrine
1
CNS
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Multiple Endocrine Neoplasia Type 2a
1
Lethal Congenital Contracture Syndrome 2
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
15
lutetium Lu 177 dotatate
14
Specimen Handling
14
cabozantinib
10
Nivolumab
10
pembrolizumab
8
Everolimus
8
gallium Ga 68 dotatate
7
Ipilimumab
6
Cisplatin
6
Carboplatin
6
Etoposide
5
trametinib
4
olaparib
4
lenvatinib
4
X-Rays
4
Lutetium-177
4
Cyclophosphamide
4
CTLA-4 Antigen
4
fluorodopa F 18
3
fludarabine
3
dabrafenib
3
cemiplimab
3
atezolizumab
3
Temozolomide
3
Surveys and Questionnaires
3
Phantoms, Imaging
3
Immunoglobulin G
3
Fluorodeoxyglucose F18
3
Disulfides
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vascular Endothelial Growth Factor A
×
Endocrine
×
90 days
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled